EN
登录

Neuralink在获得美国FDA批准开始大脑植入人体试验后获得2.8亿美元融资

Neuralink nabs $280M after scoring FDA OK to begin human trials of brain implant

Biotech Today 等信源发布 2023-10-20 00:24

可切换为仅中文


Neuralink, the Elon Musk-founded company developing an implant he’s described as “a Fitbit in your skull,” recently announced that it had gotten the go-ahead from the FDA to begin human clinical trials—and now, it has secured extra funding to see the studies through.

Neuralink是Elon Musk创立的开发植入物的公司,他被称为“头骨中的Fitbit”,最近宣布它已经从FDA开始人体临床试验,现在它已经获得了额外的资金来查看研究通过。

The outfit raised $280 million in a recent venture capital round, according to a company announcement Monday that was posted, of course, on Musk’s X, the social media platform formerly known as Twitter.

根据周一发布的公司公告,该装备在最近的一轮风险投资中筹集了2.8亿美元,该公告当然发布在Musk的X社交媒体平台上,该平台以前称为Twitter。

The series D round was led by Founders Fund, the San Francisco VC firm co-founded by serial entrepreneur Peter Thiel, who worked alongside Musk at PayPal. Founders Fund previously joined in on Neuralink’s $205 million series C financing in 2021 and has also backed SpaceX, Musk’s rocket-launching venture..

D系列由创始人基金领导,旧金山VC公司由连续企业家Peter Thiel共同创立,他与PayPal的Musk一起工作。创始人基金此前于2021年加入Neuralink价值2.05亿美元的C系列融资,并支持SpaceX,Musk的火箭发射企业。。

The new funding pushes Neuralink well past the half-billion mark. Prior to its series C and D rounds, it raised about $160 million across two additional funding tranches in 2017 and 2019, the bulk of which came from Musk himself.

新资金推动Neuralink远远超过5亿美元。在C和D系列赛之前,它在2017年和2019年的另外两笔资金中筹集了约1.6亿美元,其中大部分来自麝香本人。

The VC support will presumably be put toward the impending clinical trials of the Neuralink implant.

VC支持可能将用于Neuralink植入物即将进行的临床试验。

“We’re extremely excited about this next chapter at Neuralink,” the company wrote in this week’s announcement, adding, “If you’d like to help make the first human experience incredible and work on engineering challenges to restore vision and mobility, come join!”

该公司在本周的公告中写道:“我们对Neuralink的下一章非常兴奋,”该公司补充说:“如果您想帮助让第一次人类体验难以置信,并致力于工程挑战,以恢复愿景和移动性,请加入

The X post (née tweet) included a link to Neuralink’s job listings, which include about four dozen open intern and full-time positions in Austin, Texas, and Fremont, California. They span all areas of the company, with calls for neural, mechanical, software and electrical engineers, animal welfare specialists, neurosurgeon residents, regulatory writers and a new head of the clinical team..

X帖子(née推文)包含Neuralink工作列表的链接,其中包括在德克萨斯州奥斯汀和加利福尼亚州弗里蒙特的大约四十个开放式实习生和全职职位。他们跨越公司的所有领域,呼吁神经,机械,软件和电气工程师,动物福利专家,神经外科医生居民,监管作家和临床团队的新负责人。。

The news that the FDA had given Neuralink its blessing to begin human trials of its implant—which the company announced in late May in another post on the platform that was then still known as Twitter—came in the wake of reports that its race to the clinic had been derailed by a host of issues.

FDA已经向Neuralink表示感谢开始对其植入物进行人体试验的消息,该公司于5月下旬在该平台上的另一个帖子中宣布,该帖子当时仍被称为Twitter,这是因为有报道称其与诊所的竞赛已经受到一系列问题的困扰。

One Reuters report earlier this year, for example, claimed that Neuralink’s previous request to begin clinical trials had been denied in the spring of 2022 and that some current and former employees were skeptical that the safety and efficacy concerns raised by the FDA in its rejection could be addressed as quickly as Musk was hoping..

例如,今年早些时候的一位路透社报告称,Neuralink之前要求开始临床试验的请求在2022年春天被拒绝,一些现任和前任员工怀疑FDA在拒绝时提出的安全性和有效性问题可能会尽快解决Musk希望的问题。。

Though their skepticism was proven wrong by the FDA’s subsequent green light, Neuralink has still fallen somewhat behind Musk’s timeline: During a livestreamed presentation in November, he claimed that “probably in about six months we should be able to have our first Neuralink in a human.”

尽管FDA随后的绿灯证明他们的怀疑是错误的,但Neuralink仍然落后于Musk的时间表:在11月的一次现场流式演示中,他声称“可能在大约六个月内,我们应该能够将我们的第一个Neuralink用于人类。”

That placed the trial kickoff sometime in May; to date, the company has yet to begin enrollment for the now-approved study, but interested individuals can enroll in Neuralink’s Patient Registry, with the data shared there potentially used to determine whether they’ll be eligible to participate in the eventual trial..

这使得试验在5月的某个时候开始;迄今为止,该公司尚未开始参加现已批准的研究,但感兴趣的个人可以参加Neuralink的患者登记处,那里共享的数据可能用于确定他们是否有资格参加最终试验。。